We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01512173
Recruitment Status : Completed
First Posted : January 19, 2012
Last Update Posted : October 30, 2014
Information provided by (Responsible Party):
Pierre Fabre Dermatology

Brief Summary:

There is an unsatisfied medical need for a first-line treatment of localized uncomplicated proliferating Infantile Hemangioma with a good benefit/risk profile.

Pierre Fabre Dermatologie has developed a new formulation of propranolol (V0400 GL 01A) which is a topical gel adapted to paediatric use.

The objective of this study is to evaluate topical propranolol efficacy and safety in the management of localized hemangioma.

Condition or disease Intervention/treatment Phase
Infantile Hemangioma Drug: propranolol gel Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo.
Study Start Date : January 2012
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birthmarks

Arm Intervention/treatment
Experimental: propranolol gel Drug: propranolol gel
Topical administration twice daily

Placebo Comparator: Placebo Drug: Placebo
Topical administration twice daily

Primary Outcome Measures :
  1. Complete/nearly complete resolution of the Infantile Hemangioma at week 12. [ Time Frame: week 12 ]
    Complete/nearly complete resolution of the Infantile Hemangioma at week 12 compared to baseline

Secondary Outcome Measures :
  1. On-site parent(s) or guardian(s) qualitative assessments of efficacy [ Time Frame: week 2 , week 4, week 8, week 12 and week 24 ]
    categorical endpoints for Infantile Hemangioma evolution (4-points scale)

  2. Persistence of efficacy 12 weeks after the end of treatment [ Time Frame: Week 24 ]
    Persistence of complete/nearly complete resolution of the Infantile Hemangioma at week 24 compared to week 12.

  3. Safety profile (descriptive analysis of AE) [ Time Frame: Day 0, week 2, week 4, week 8, week 12 and week 24 ]
  4. Local tolerance of the propranolol gel(description over time by treatment group) [ Time Frame: week 2, week 4, week 8 and week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Days to 150 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • only one proliferating Infantile Hemangioma present anywhere on the body except on the head, the neck, the hands and on the diaper area, with largest diameter diameter ≥ 1cm and ≤ 5 cm.

Main Exclusion Criteria:

  • more than one Infantile Hemangioma with largest diameter ≥ 1cm
  • medically unstable health status that may interfere with his/her ability to complete the study
  • Infantile Hemangioma requires, according to Investigator's judgment, a systemic treatment
  • the patient has previously been administered treatment for IH or surgical and/or medical procedures (e.g. laser therapy) have been performed to treat the IH

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01512173

Show Show 17 study locations
Sponsors and Collaborators
Pierre Fabre Dermatology
Layout table for additonal information
Responsible Party: Pierre Fabre Dermatology
ClinicalTrials.gov Identifier: NCT01512173    
Other Study ID Numbers: V00400 GL 2 01 1A
2011-003144-50 ( EudraCT Number )
First Posted: January 19, 2012    Key Record Dates
Last Update Posted: October 30, 2014
Last Verified: October 2014
Keywords provided by Pierre Fabre Dermatology:
Propranolol gel
capillary neoplasm
vascular tissue
neoplasm by histologic type
therapeutic uses
pharmacologic actions
adrenergic beta-antagonists
adrenergic antagonist
adrenergics agent
neurotransmitter agent
molecular mechanism of pharmacological action
physiological effects of drugs
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemangioma, Capillary
Port-Wine Stain
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Skin Abnormalities
Congenital Abnormalities
Skin Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents